New PT is out now, with a razor-sharp focus on the importance of youth in shaping the future of our industry. We’ll also be taking on antimicrobial resistance, dissecting mergers & acquisitions and – of course – pondering whether viruses are dead or alive. Meanwhile, as wider healthcare emerges into a new era, we will also explore how the enduring relationship between NHS and pharma will evolve. There are also further intrepid musings around AI, real-life data and targeted therapies.